[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai General Hospital, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":142},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,71,96,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100612774","apos-associated-with-respiratory-viral-infections-before-and-during-early-pregnancy-100612774",false,"NCT07257952","APOs Associated With Respiratory Viral Infections Before and During Early Pregnancy","An Observational Study on the Risk of Adverse Maternal and Infant Outcomes Associated With Respiratory Viral Infections Before and During Early Pregnancy","APO","Inclusion Criteria:\n\n* Female;\n* Age 20 to 45 years old;\n* Physician-diagnosed acute respiratory viral infection occurring within 6 months before pregnancy and\u002For at \\\u003C24 weeks of gestation.\n\nExclusion Criteria:\n\n* Pregestational T1D or T2D;\n* Long-term use of immunosuppressants or glucocorticoids;\n* Diseases that severely affect immune or metabolic function (e.g., HIV, SLE, rheumatoid arthritis);\n* Severe mental illness or cognitive impairment;\n* Women whose electronic medical records lack GDM screening and delivery records.","FEMALE","20 Years","45 Years",{"count":21,"type":22},1440,"ESTIMATED","OBSERVATIONAL","Adverse pregnancy outcomes (APOs) are a collection of conditions that have short-term and long-term effects of complications related to pregnancy and childbirth on pregnant women and their fetuses, including hypertensive disorders of pregnancy, gestational diabetes, preterm birth, large for gestational age, among others. Nearly 30% of all women experience an adverse pregnancy outcome during their reproductive years. Although, respiratory viral infections with epidemic and pandemic potential pose an omnipresent threat to public health, research focusing specifically on the maternal-infant population remains relatively scarce.\n\nStudies conducted in USA found that among pregnant women infected with influenza, the proportion of those with gestational hypertension or diabetes was higher than in pregnant women without influenza infection (13.9% vs. 11.1%).\n\nResearch on the impact of respiratory viral infections on perinatal outcomes in China is limited, and we aim to establish of a large-scale, retroprospective maternal-child cohorts. This cohort study will systematically collect longitudinal data (e.g., detailed clinical history, timing of infection\u002Fvaccination, complication of pregnancy, and APOs) to assess the risk of respiratory viral infections to APOs, as well as facilitate multidisciplinary research.",[26,27],"Respiratory Viral Infections","Adverse Pregnancy Outcomes",[29,30,31,32],"Adverse pregnancy outcome","Preterm birth","Gestational diabetes mullitus","Respiratory Viral Infection","NOT_YET_RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-23","ACTUAL",{"date":39,"type":22},"2026-07-05",{"date":41,"type":22},"2028-11-30",{"name":43,"class":44},"Shanghai General Hospital, China","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100559651","monitoring-of-antimicrobial-resistance-based-on-metagenomics-analyses-in-pneumonia-patients-100559651","NCT06566898","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study","Inclusion Criteria:\n\n* Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.\n* Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.\n\nExclusion Criteria:\n\n* Patients whose biological samples may be contaminated;\n* Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.","ALL",{"count":54,"type":22},800,"Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions:\n\n1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ?\n2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ?\n3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?",[57,58,59,60],"Pneumonia","Next-generation Sequencing","Microbiome","Antimicrobial Resistance",[57,62,59,60],"Next-generation sequencing","RECRUITING",{"date":36,"type":37},{"date":66,"type":37},"2024-08-01",{"date":68,"type":22},"2026-09-30",{"name":43,"class":44},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":52,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":70},"100614559","xinqiao-high-risk-cohort-of-diabetesnice-100614559","NCT07281170","Xinqiao High-risk Cohort of Diabetes(NICE)","Xinqiao High-risk Cohort of Diabetes","Inclusion Criteria:\n\n* Individuals who provide written informed consen\n* Have access to a smartphone\n* Hamily history of diabetes or abnormal microglucose level detected once\n* Age ≥18 years at the time of consent\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study\n* recently surgical histories, trauma, acute cardiovascular complications, or infectious diseases","20 Months","79 Years",{"count":81,"type":22},7000,"Objective: 1. To systematically screen the high-risk population of diabetes in Xinqiao area, understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in the high-risk population and patients with prediabetes, and establish the first standardized research cohort of high-risk patients and prediabetes patients in Songjiang area.\n\n2\\. Use CGM monitoring technology to identify the high-risk groups of diabetes and the fluctuation of blood glucose in pre-diabetes, understand their ophthalmology and bone density, observe the annual conversion rate of diabetes, find effective interventions, move forward the management of diabetes, and create a new model for the management of high-risk groups of diabetes.\n\nResearch content: Part I: Establishing the first standardized diabetes high-risk population research cohort in Songjiang area The initiative focuses on early screening for high-risk populations with diabetes, shifting the focus downward and advancing prevention measures to detect diabetes at an earlier stage and initiate timely intervention. In Xinqiao District, all high-risk screening cases will undergo medical history documentation, anthropometric measurements, laboratory testing, and regular follow-ups. Standard oral glucose tolerance test (OGTT) methods will be employed to assess fasting blood glucose levels, insulin sensitivity, 2-hour postprandial glucose and insulin levels after a 75g glucose load, and glycated hemoglobin levels. Beyond evaluating glucose metabolism, the screening will also detect other metabolic disorders through routine blood tests including urinalysis, liver\u002Fkidney function tests, uric acid levels, lipid profiles, thyroid function, and urine protein\u002Fcreatinine ratio. The establishment of this premium high-risk screening program in Xinqiao Community will create Songjiang District's first standardized research cohort for diabetes mellitus (DM) and prediabetes patients, carrying significant strategic importance.\n\nPart II: By integrating Clinical Monitoring (CGM) technology with ophthalmological evaluations and bone density ultrasound examinations, we identify characteristics of high-risk diabetic populations and track their disease progression. The CGM system (with auxiliary devices such as the Shansheng Dynamic Glucose Monitoring System) is utilized to monitor blood glucose fluctuations in these individuals. Concurrently, comprehensive ophthalmic assessments-including visual acuity tests, intraocular pressure measurements, fundus photography, OCT scans, OCTA imaging, and SLO examinations-are conducted alongside bone density testing. Annual follow-up evaluations are performed to track clinical outcomes.\n\nResearch innovation points and expected results: Research innovation points:\n\nEstablish the first standardized research cohort of high-risk and pre-diabetic patients in Songjiang area; move forward the management of diabetes, and create a new management model for high-risk groups of diabetes.\n\nanticipated results\n\n1. Establish a new standardized diabetes high-risk population research cohort with large sample size.\n2. Observe the metabolic characteristics, blood glucose fluctuation, ophthalmic conditions and bone density of high-risk groups with diabetes.\n3. Find effective interventions to reduce the annual conversion rate of diabetes.",[84],"Pre Diabetic",[86,84,87],"xinqiao","NICE","2025-12-01",{"date":90,"type":37},"2025-12-15",{"date":92,"type":37},"2019-10-08",{"date":94,"type":22},"2034-12-31",{"name":43,"class":44},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":70},"100605394","shanghai-clinical-cohort-of-hyperglycemia-in-pregnancy-100605394","NCT07161947","Shanghai Clinical Cohort of Hyperglycemia in Pregnancy","Shanghai Clinical Cohort-Hyperglycemia in Pregnancy (Reserved)","SHINE","Inclusion Criteria:\n\n* Pregnant individuals who provide written informed consent\n* At enrollment, meet one of the following:\n\n  1\\. Gestational diabetes mellitus (GDM) diagnosed by a 75-g oral glucose tolerance test (OGTT) using Chinese Diabetes Society (CDS) 2024 thresholds (any one of: fasting plasma glucose ≥5.1 mmol\u002FL, 1-h ≥10.0 mmol\u002FL, or 2-h ≥8.5 mmol\u002FL); or 2. Pre-gestational diabetes (type 1 or type 2) documented prior to pregnancy or meeting diabetes criteria at the first prenatal visit (e.g., fasting ≥7.0 mmol\u002FL, 2-h OGTT ≥11.1 mmol\u002FL, or HbA1c ≥6.5%); or 3. At high risk for GDM, defined a priori as ≥1 of the following: prior GDM; prior macrosomic infant (≥4,000 g); pre-pregnancy BMI ≥24 kg\u002Fm²; age ≥45 years; high-density lipoprotein cholesterol \\\u003C1 mmol\u002FL, and\u002For triglyceride levels \\>2.8 mmol\u002FL; first-degree family history of diabetes; polycystic ovary syndrome (PCOS); history of coronary heart disease; chronic hypertension and repeated positive fasting urinary glucose in early pregnancy\n* Age ≥18 years at the time of consent\n* Willing and able to attend postpartum assessments (OGTT at 6 weeks, 12 months, and annually thereafter), with planned follow-up ≥3 years\n\nExclusion Criteria:\n\n* Current or history of illicit drug use or substance abuse\n* Presence of an active infectious disease, including but not limited to: viral hepatitis, sexually transmitted infections or tuberculosis\n* Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study","18 Years",{"count":106,"type":22},4000,"10 Years","Establish a high-quality clinical cohort of hyperglycemia in pregnancy. Develop subtype-specific, end-to-end standards for diagnosis, treatment, and follow-up across the preconception, pregnancy, and postpartum phases. These standards will lay a solid foundation for efficient, high-quality clinical research.",[110,111],"Hyperglycemia in Pregnant Diabetic Patients","Gestatiaonl Diabetes Mellitus","2025-09-08",{"date":114,"type":37},"2025-09-09",{"date":116,"type":37},"2025-04-01",{"date":118,"type":22},"2027-12-31",{"name":43,"class":44},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":128,"enrollmentInfo":129,"targetDuration":107,"studyType":23,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":70},"100602620","gongji-pregnancy-endorine-cohort-study-100602620","NCT07125885","Gongji Pregnancy Endorine Cohort Study","Serological, Metabolomic, and Genomic Studies of Endocrine Disorders in Pregnancy","GREAT","Inclusion Criteria:\n\n* Women preparing for pregnancy or pregnant women or within 1 year after giving birth\n* Age ≥ 18 years old\n* Signed the informed consent form to voluntarily enroll in the management follow-up\n\nExclusion Criteria:\n\n* Individuals who are unable to communicate normally and those who are unwilling to cooperate\n* Pregnant women with severe organic diseases or mental illnesses\n* Any condition deemed by the investigator to affect eligibility for the study","50 Years",{"count":130,"type":22},3000,"To explore the relationship between genetic factors, lifestyle, and drug interventions and the occurrence, development, adverse pregnancy outcomes, and postpartum maternal-infant outcomes of gestational endocrine diseases.",[111,133,110],"Thyroid Disease Pregnancy","2025-08-09",{"date":136,"type":37},"2025-08-15",{"date":138,"type":37},"2023-05-05",{"date":140,"type":22},"2043-12-31",{"name":43,"class":44},""]